FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders [0.03%]
FAAH和MAGL抑制作用：治疗物质使用障碍的新兴方法
Charlie J Maddox,Francis S Lee,Anjali M Rajadhyaksha et al.
Charlie J Maddox et al.
Substance use disorder (SUD) remains a critical public health issue characterized by high rates of relapse and limited effective pharmacotherapies, particularly for non-opioid substances. A key challenge in addressing SUD lies in the persis...
Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort [0.03%]
从抗CD20疗法转换为克拉布利定以及反之：德国复发性多发性硬化症队列的分析
Franz Felix Konen,Steffen Pfeuffer,Konstantin Fritz Jendretzky et al.
Franz Felix Konen et al.
Anti-CD20 antibodies and cladribine are established therapies for active relapsing multiple sclerosis (RMS). Increasing evidence suggests that switching between these therapies may be beneficial in patients with ongoing disease activity und...
New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment [0.03%]
Lafora病的新治疗策略：静脉输注VAL-1221的安全性、有效性和药代动力学及代谢组谱的评估
Lorenzo Muccioli,Maria Tappatà,Andrea Farolfi et al.
Lorenzo Muccioli et al.
Lafora disease (LD) is a fatal progressive myoclonus epilepsy that affects previously healthy adolescents and lacks effective treatments. It is caused by pathogenic variants in EPM2A or NHLRC1, leading to the accumulation of polyglucosan in...
Commentary on: "Delayed necrostatin-1s infusion attenuates cystic white matter injury in preterm fetal sheep." [0.03%]
述评：“延期施用Necrostatin-1s可减轻早产胎儿绵羊的囊状白质损伤”
Stephen A Back
Stephen A Back
Ferroptosis inhibitor UAMC-3203 preserves memory and prevents anxiety-like behavior but worsens aversive learning in diabetic rats after stroke in a randomized preclinical trial [0.03%]
随机临床前试验：Ferroptosis抑制剂UAMC-3203可保存糖尿病卒中大鼠记忆并防止类似焦虑行为，但会加重厌恶学习能力下降现象
Mia Edgerton-Fulton,Ashley Phoenix,Yasir Abdul et al.
Mia Edgerton-Fulton et al.
Diabetes increases post-stroke mortality and cognitive impairment (PCSI). We previously demonstrated that iron chelation during the subacute phase enhances cognitive outcomes after stroke in experimental diabetes. Here, we hypothesized that...
Uncovering the role of c-Fos in the bidirectional relationship between depression/anxiety behaviors and α-synuclein propagation in Parkinson's disease [0.03%]
揭示c-Fos在抑郁症/焦虑症行为与帕金森病α-突触核蛋白传播的双向关系中的作用
Soo-Jeong Kim,Jae-Bong Kim,Seonghui Ham et al.
Soo-Jeong Kim et al.
Parkinson's disease (PD) presents with both motor and non-motor symptoms, including depression and anxiety, which often precede motor onset, yet the mechanisms linking these affective symptoms to PD pathology remain unclear. In this study, ...
A 16-amino acid peptide delays the progression of motor neuron degeneration and pathogenic symptoms in ALS models [0.03%]
一种十六肽能延缓ALS模型中运动神经元退行性病变及病理症状的发展
Cheng-Yung Lin,Bing-Chang Lee,Po-Hsiang Zhang et al.
Cheng-Yung Lin et al.
Amyotrophic lateral sclerosis (ALS) is a progressive motor neurons (MNs) degenerative disease. Despite advancements in understanding ALS pathogenesis, drug development lags far behind. The reduced secretion of phosphoglycerate kinase 1 (Pgk...
Simvastatin-induced neuroprotective effect after brain injury is mediated by mitochondrial protection through modulation of the 18 kDa translocator protein [0.03%]
辛伐他汀通过调节18 kDa转位蛋白介导的线粒体保护作用对脑损伤产生的神经保护效应
Reem Sakas,Tom Fishboom,Aviv Ben-Menashe et al.
Reem Sakas et al.
Traumatic brain injury (TBI) remains a leading cause of mortality and chronic disability. Among therapeutic agents investigated, simvastatin has emerged as a potential therapeutic opportunity for management of TBI although its mechanism of ...
Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study [0.03%]
帕金森病的饮食补充分之盐：一项开放标签的目标参与研究
Jeffrey L B Bohnen,Stiven Roytman,Travis P Wigstrom et al.
Jeffrey L B Bohnen et al.
Short-chain fatty acids such as butyrate (key signaling molecules that influence the gut-brain axis and modulate inflammatory, mitochondrial, and transcriptional regulatory processes) are attracting interest as potential treatments for neur...